| Row | STUDYID | DOMAIN | ETCD | ELEMENT | TESTRL | TEENRL | TEDUR |
|---|
| 1 | EX2 | TE | SCRN | Screen | Informed consent | 2 weeks after start of Element | P14D |
| 2 | EX2 | TE | USL | USUALUsual | First dose of Study product administration in Product Administration Exposure Epoch, where product is the usual tobacco product | 2 weeks after start of Element | P14D |
| 3 | EX2 | TE | TPA | TP A | First dose of Study product administration in Product Administration Exposure Epoch, where dose is tobacco product A | 2 weeks after start of Element | P14D |
| 4 | EX2 | TE | TPB | TP B | First dose of Study product administration in Product Administration Exposure Epoch, where dose is tobacco product B | 2 weeks after start of Element | P14D |
| 5 | EX2 | TE | REST | Rest | After last dose of preceding Study Product Administration Exposure Epoch | 1 week after start of Element | P7D |
| 6 | EX2 | TE | FU | Follow-up | After last dose of last Study preceding Product Administration Exposure Epoch | 3 weeks after start of Element | P21D |